NCT07110584 2026-03-05
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
ModeX Therapeutics, An OPKO Health Company
Shanghai Institute Of Biological Products
Advenchen Laboratories, LLC
Chipscreen Biosciences, Ltd.